Kite Pharma Company Profile (NASDAQ:KITE)

About Kite Pharma

Kite Pharma logoKite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KITE
  • CUSIP:
Key Metrics:
  • Previous Close: $60.04
  • 50 Day Moving Average: $58.29
  • 200 Day Moving Average: $51.62
  • 52-Week Range: $38.41 - $89.84
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.06
  • P/E Growth: 0.00
  • Market Cap: $2.88B
  • Outstanding Shares: 49,596,000
  • Beta: 2.48
Profitability:
  • Net Margins: -873.86%
  • Return on Equity: -32.91%
  • Return on Assets: -28.11%
Debt:
  • Current Ratio: 12.59%
  • Quick Ratio: 12.59%
Additional Links:
Companies Related to Kite Pharma:

Analyst Ratings

Consensus Ratings for Kite Pharma (NASDAQ:KITE) (?)
Ratings Breakdown: 2 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.87)
Consensus Price Target: $76.62 (27.61% upside)

Analysts' Ratings History for Kite Pharma (NASDAQ:KITE)
Show:
DateFirmActionRatingPrice TargetDetails
9/27/2016FBR & CoReiterated RatingOutperform$78.00View Rating Details
9/27/2016BTIG ResearchReiterated RatingNeutralView Rating Details
9/27/2016Jefferies GroupReiterated RatingBuy$72.00View Rating Details
9/27/2016Barclays PLCBoost Price TargetEqual Weight$60.00 -> $65.00View Rating Details
9/22/2016Stifel NicolausReiterated RatingBuy$74.00View Rating Details
8/9/2016MizuhoSet Price TargetBuy$80.00View Rating Details
8/9/2016Maxim GroupReiterated RatingBuy$87.00 -> $77.00View Rating Details
7/26/2016Canaccord GenuityReiterated RatingBuy$75.00View Rating Details
6/20/2016Cowen and CompanyReiterated RatingBuyView Rating Details
6/2/2016Raymond James Financial Inc.Initiated CoverageOutperform$61.00View Rating Details
5/18/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
3/20/2016SunTrust Banks Inc.Reiterated RatingBuy$70.00View Rating Details
2/25/2016Citigroup Inc.Initiated CoverageBuy$67.00View Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$111.00 -> $92.00View Rating Details
12/15/2015Standpoint ResearchUpgradeHold -> BuyView Rating Details
8/14/2015GuggenheimReiterated RatingBuyView Rating Details
5/5/2015Credit Suisse Group AGReiterated RatingOutperform$79.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Kite Pharma (NASDAQ:KITE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
8/8/2016Q216($1.21)($0.91)$4.86 million$4.80 millionViewN/AView Earnings Details
5/9/2016Q116($1.08)($0.60)$4.61 million$5.10 millionViewN/AView Earnings Details
2/29/2016Q4($0.71)($0.54)$4.54 million$4.89 millionViewListenView Earnings Details
11/12/2015Q315($0.64)($0.38)$4.06 million$5.10 millionViewListenView Earnings Details
8/10/2015Q215($0.40)($0.48)$2.51 million$4.40 millionViewListenView Earnings Details
5/15/2015Q115$0.12($0.36)$19.70 million$2.90 millionViewN/AView Earnings Details
3/26/2015Q414($0.20)($0.33)ViewN/AView Earnings Details
11/14/2014Q314($0.23)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kite Pharma (NASDAQ:KITE)
Current Year EPS Consensus Estimate: $-5.92 EPS
Next Year EPS Consensus Estimate: $-6.63 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.37)($0.93)($1.09)
Q2 20163($1.30)($1.15)($1.24)
Q3 20163($1.74)($1.66)($1.70)
Q4 20163($2.18)($2.05)($2.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Kite Pharma (NASDAQ:KITE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kite Pharma (NASDAQ:KITE)
Insider Ownership Percentage: 20.60%
Institutional Ownership Percentage: 75.28%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2016Jeffrey WiezorekSVPSell1,500$58.24$87,360.00View SEC Filing  
8/25/2016Cynthia M. ButittaCOOSell10,000$58.28$582,800.00View SEC Filing  
8/15/2016Helen Susan KimEVPSell35,900$60.27$2,163,693.00View SEC Filing  
8/1/2016Jeffrey WiezorekSVPSell1,500$56.90$85,350.00View SEC Filing  
7/25/2016Cynthia M ButittaCOOSell10,000$50.94$509,400.00View SEC Filing  
7/1/2016Jeffrey WiezorekSVPSell1,500$50.00$75,000.00View SEC Filing  
6/27/2016Cynthia M ButittaCOOSell20,000$50.71$1,014,200.00View SEC Filing  
6/6/2016Roy DoumaniDirectorSell10,000$57.91$579,100.00View SEC Filing  
6/1/2016Jeffrey WiezorekSVPSell3,000$50.65$151,950.00View SEC Filing  
4/4/2016Cynthia M ButittaCFOSell10,000$50.00$500,000.00View SEC Filing  
3/15/2016Jeffrey WiezorekSVPSell9,000$44.88$403,920.00View SEC Filing  
3/15/2016Margo R RobertsInsiderSell8,506$45.23$384,726.38View SEC Filing  
3/15/2016Rizwana F SprouleVPSell8,500$45.27$384,795.00View SEC Filing  
3/1/2016Cynthia M. ButittaCFOSell10,000$50.03$500,300.00View SEC Filing  
2/17/2016Margo R. RobertsinsiderSell9,632$45.06$434,017.92View SEC Filing  
2/17/2016Rizwana F. SprouleVPSell9,567$45.08$431,280.36View SEC Filing  
2/12/2016Margo R. RobertsinsiderSell18,750$64.16$1,203,000.00View SEC Filing  
2/2/2016Cynthia M. ButittaCFOSell1,900$50.13$95,247.00View SEC Filing  
2/1/2016Marc BetterVPSell9,000$47.34$426,060.00View SEC Filing  
1/27/2016Cynthia M. ButittaCFOSell8,100$51.62$418,122.00View SEC Filing  
1/19/2016Rizwana F. SprouleVPSell9,567$55.49$530,872.83View SEC Filing  
1/15/2016Jeffrey WiezorekSVPSell9,000$55.26$497,340.00View SEC Filing  
1/15/2016Margo R. RobertsinsiderSell6,145$55.22$339,326.90View SEC Filing  
1/4/2016Marc BetterVPSell9,000$61.53$553,770.00View SEC Filing  
12/28/2015Cynthia M. ButittaCFOSell10,000$61.56$615,600.00View SEC Filing  
11/27/2015Cynthia M. ButittaCFOSell15,000$86.45$1,296,750.00View SEC Filing  
11/16/2015Jeffrey WiezorekSVPSell9,000$78.08$702,720.00View SEC Filing  
11/16/2015Margo R. RobertsinsiderSell6,145$78.16$480,293.20View SEC Filing  
11/16/2015Rizwana F. SprouleVPSell9,567$78.13$747,469.71View SEC Filing  
11/2/2015David D. ChangEVPSell7,700$71.08$547,316.00View SEC Filing  
11/2/2015Marc BetterVPSell9,000$71.07$639,630.00View SEC Filing  
10/27/2015Cynthia M. ButittaCFOSell10,000$69.91$699,100.00View SEC Filing  
10/15/2015Jeffrey WiezorekSVPSell9,000$62.59$563,310.00View SEC Filing  
10/15/2015Margo R. RobertsinsiderSell6,145$62.57$384,492.65View SEC Filing  
10/15/2015Rizwana F. SprouleVPSell9,567$62.58$598,702.86View SEC Filing  
10/1/2015David D. ChangEVPSell7,700$55.11$424,347.00View SEC Filing  
10/1/2015Marc BetterVPSell9,000$54.81$493,290.00View SEC Filing  
9/28/2015Cynthia M. ButittaCFOSell10,000$55.87$558,700.00View SEC Filing  
9/15/2015Margo R. RobertsinsiderSell6,145$64.33$395,307.85View SEC Filing  
9/15/2015Rizwana F. SprouleVPSell9,567$64.36$615,732.12View SEC Filing  
9/8/2015David D. ChangEVPSell7,700$55.00$423,500.00View SEC Filing  
9/1/2015Marc BetterVPSell9,000$51.81$466,290.00View SEC Filing  
8/27/2015Cynthia M. ButittaCFOSell10,000$53.62$536,200.00View SEC Filing  
8/17/2015Jeffrey WiezorekVPSell9,000$60.87$547,830.00View SEC Filing  
8/17/2015Margo R RobertsInsiderSell6,145$60.90$374,230.50View SEC Filing  
7/1/2015David D ChangEVPSell7,700$61.92$476,784.00View SEC Filing  
7/1/2015Marc BetterVPSell9,000$61.90$557,100.00View SEC Filing  
6/29/2015Cynthia M ButittaCFOSell10,000$59.65$596,500.00View SEC Filing  
6/25/2015Jeffrey WiezorekVPBuy4,000$17.00$68,000.00View SEC Filing  
6/15/2015David D ChangEVPSell7,700$56.98$438,746.00View SEC Filing  
6/15/2015Margo R RobertsInsiderSell8,625$56.99$491,538.75View SEC Filing  
6/15/2015Rizwana F SprouleVPSell9,567$56.98$545,127.66View SEC Filing  
6/2/2015Ran NussbaumDirectorSell305,434$55.35$16,905,771.90View SEC Filing  
6/1/2015Marc BetterVPSell9,000$54.60$491,400.00View SEC Filing  
6/1/2015Ran NussbaumDirectorSell80,760$55.34$4,469,258.40View SEC Filing  
4/27/2015Cynthia M ButittaCFOSell10,000$59.76$597,600.00View SEC Filing  
3/30/2015Ran NussbaumDirectorSell193,730$60.45$11,710,978.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Kite Pharma (NASDAQ:KITE)
DateHeadline
News IconStocks Tumbling to New Lows- Kite Pharma, Inc. (NASDAQ:KITE), St. Jude Medical Inc. (NYSE:STJ) - Street Wise Report (press release) (blog) (NASDAQ:KITE)
streetwisereport.com - September 28 at 10:44 AM
News IconAnalysts Valuations For Two Stocks: Kite Pharma Inc (NASDAQ:KITE), Nuance Communications Inc. (NASDAQ:NUAN) - The Voice Registrar (NASDAQ:KITE)
voiceregistrar.com - September 28 at 10:44 AM
fool.com logoHow Kite Pharma Could Change Cancer Treatment Forever - Motley Fool (NASDAQ:KITE)
www.fool.com - September 28 at 10:44 AM
247wallst.com logoRed-Hot Biotechs Highlight Jefferies Top Stocks to Buy This Week (NASDAQ:KITE)
247wallst.com - September 28 at 10:44 AM
rttnews.com logoKite Pharma Inc. (KITE) Is Up Sharply On Study Results (NASDAQ:KITE)
www.rttnews.com - September 27 at 5:47 PM
schaeffersresearch.com logoBuzz Stocks: Amgen, Inc., Kite Pharma Inc, and WebMD Health Corp. (NASDAQ:KITE)
www.schaeffersresearch.com - September 27 at 5:47 PM
nasdaq.com logoHow Kite Pharma Could Change Cancer Treatment Forever (NASDAQ:KITE)
www.nasdaq.com - September 27 at 5:47 PM
investorplace.com logoKite Pharma Inc Scores Big on Positive Clinical Trial (KITE) (NASDAQ:KITE)
investorplace.com - September 27 at 2:12 PM
News IconNews review of 2 biotech stocks: Kite Pharma, Inc. (NASDAQ:KITE), Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - The Voice Registrar (NASDAQ:KITE)
voiceregistrar.com - September 27 at 10:26 AM
marketwatch.com logoKite Pharma shares rally after study shows cancer drug benefit - MarketWatch (NASDAQ:KITE)
www.marketwatch.com - September 27 at 10:26 AM
insidermonkey.com logoWhy Kite Pharma, Rice Energy, BlackBerry, and More Are Trending (NASDAQ:KITE)
www.insidermonkey.com - September 27 at 10:26 AM
businesswire.com logoKite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma (NHL) (NASDAQ:KITE)
www.businesswire.com - September 26 at 5:53 PM
4-traders.com logoKITE PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:KITE)
www.4-traders.com - September 26 at 5:53 PM
marketwatch.com logoKite Pharma shares rally after study shows cancer drug benefit (NASDAQ:KITE)
www.marketwatch.com - September 26 at 5:53 PM
News IconKite immunotherapy drug helps blood cancer patients in study (NASDAQ:KITE)
www.channelnewsasia.com - September 26 at 5:53 PM
rttnews.com logoKite Pharma Inc. (KITE) Is Climbing On Study Results (NASDAQ:KITE)
www.rttnews.com - September 26 at 5:53 PM
News IconKite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphom... (NASDAQ:KITE)
ih.advfn.com - September 26 at 5:53 PM
News Icon2 Stocks Analyst-Opinion Need Close Attention KAR Auction ... - The Voice Registrar (NASDAQ:KITE)
voiceregistrar.com - September 24 at 5:23 PM
News IconBiotech Stocks To Put On Your Watch List: Kite Pharma, Inc. (NASDAQ:KITE), Achillion Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:KITE)
voiceregistrar.com - September 22 at 9:01 AM
nasdaq.com logoFirst Week of November 18th Options Trading For Kite Pharma (KITE) - Nasdaq (NASDAQ:KITE)
www.nasdaq.com - September 22 at 9:01 AM
News IconNews review of 2 biotech stocks: Zafgen, Inc. (NASDAQ:ZFGN), Kite ... - The Voice Registrar (NASDAQ:KITE)
voiceregistrar.com - September 22 at 9:01 AM
smarteranalyst.com logoStock Update (NASDAQ:KITE): Kite Pharma Inc Announces Exclusive License with the National Institutes of Health - Smarter Analyst (NASDAQ:KITE)
www.smarteranalyst.com - September 22 at 9:01 AM
fool.com logoJuno Therapeutics and Kite Pharma: The Danger of Alarmingly Thin ... - Motley Fool (NASDAQ:KITE)
www.fool.com - September 22 at 9:01 AM
capitalcube.com logoETF’s with exposure to Kite Pharma, Inc. : September 21, 2016 (NASDAQ:KITE)
www.capitalcube.com - September 21 at 4:04 PM
thestreet.com logoKite Pharma Isn't Airborne Yet (NASDAQ:KITE)
realmoney.thestreet.com - September 21 at 4:04 PM
News IconKite Pharma Announces Exclusive License with the National Institutes of Health ... (NASDAQ:KITE)
sports.yahoo.com - September 21 at 9:58 AM
streetinsider.com logoKite Pharma (KITE) Reports Exclusive License with NIH for TCR Product Candidates (NASDAQ:KITE)
www.streetinsider.com - September 21 at 9:58 AM
nasdaq.com logoFirst Week of November 18th Options Trading For Kite Pharma (KITE) (NASDAQ:KITE)
www.nasdaq.com - September 21 at 9:58 AM
News IconKite Pharma, Inc — Shares in Focus (NASDAQ:KITE)
myhealthbowl.com - September 21 at 9:58 AM
businesswire.com logoKite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors ... (NASDAQ:KITE)
www.businesswire.com - September 21 at 9:58 AM
smarteranalyst.com logoStock Update (NASDAQ:KITE): Kite Pharma Inc Announces Exclusive License with the National Institutes of Health (NASDAQ:KITE)
www.smarteranalyst.com - September 21 at 9:58 AM
publicnow.com logoKite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors Expressing Mutated KRAS (NASDAQ:KITE)
www.publicnow.com - September 21 at 9:58 AM
News IconEarnings According to Analysts for Kite Pharma, Inc. (NASDAQ:KITE)? - Frisco Fastball (NASDAQ:KITE)
friscofastball.com - September 18 at 5:31 PM
marketnewsvideo.com logoNoteworthy Friday Option Activity: CAG, KITE, JCP (NASDAQ:KITE)
www.marketnewsvideo.com - September 17 at 10:21 AM
News IconKite Pharma Inc. (KITE) Trading 3.7% Higher | NewsDen - NewsDen (NASDAQ:KITE)
newsden.net - September 16 at 5:40 PM
fxpips.com logoAFTER HOURS Quick Review – Top 10 Most Advanced Stocks (NASDAQ:KITE)
www.fxpips.com - September 15 at 3:43 PM
capitalcube.com logoKite Pharma, Inc. – Value Analysis (NASDAQ:KITE) : September 15, 2016 (NASDAQ:KITE)
www.capitalcube.com - September 15 at 3:43 PM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Kite Pharma, Inc. (NASDAQ:KITE) - Frisco Fastball (NASDAQ:KITE)
friscofastball.com - September 15 at 9:02 AM
News IconHot Biotech Stocks Recap: Intrexon Corporation (NYSE:XON), Kite Pharma, Inc. (NASDAQ:KITE) - The Voice Registrar (NASDAQ:KITE)
voiceregistrar.com - September 15 at 9:02 AM
News IconThe Key Numbers To Watch From Kite Pharma, Inc. (NASDAQ:KITE)'s Earnings - The Voice Registrar (NASDAQ:KITE)
voiceregistrar.com - September 14 at 5:55 PM
capitalcube.com logoKite Pharma, Inc. breached its 50 day moving average in a Bearish Manner : KITE-US : September 14, 2016 (NASDAQ:KITE)
www.capitalcube.com - September 14 at 10:02 AM
nasdaq.com logoPeek Under The Hood: IYH Has 14% Upside (NASDAQ:KITE)
www.nasdaq.com - September 13 at 10:39 AM
News IconResearch Reports Coverage on Biotech Stocks -- Northwest Biotherapeutics, Radius Health, Spectrum Pharma, and Kite Pharma (NASDAQ:KITE)
www.kait8.com - September 12 at 10:33 AM
benzinga.com logoBTIG Is 'Generally Skeptical' On Kite Pharma Expectations - Benzinga (NASDAQ:KITE)
www.benzinga.com - September 2 at 10:39 AM
finance.yahoo.com logoKite Pharma to Participate in September 2016 Investor Conferences (NASDAQ:KITE)
finance.yahoo.com - September 1 at 5:43 PM
finance.yahoo.com logoKite Pharma to Participate in September 2016 Investor Conferences - Yahoo Finance (NASDAQ:KITE)
finance.yahoo.com - September 1 at 8:54 AM
benzinga.com logoBTIG Is 'Generally Skeptical' On Kite Pharma Expectations (NASDAQ:KITE)
www.benzinga.com - August 31 at 10:37 AM
News IconUpcoming Earnings Report: Kite Pharma, Inc. (NASDAQ:KITE) - The Voice Registrar (NASDAQ:KITE)
voiceregistrar.com - August 30 at 5:51 PM
finance.yahoo.com logoVetr Crowd Slowly Turning Positive On Kite Pharma, Now Rates It A Buy (NASDAQ:KITE)
finance.yahoo.com - August 30 at 5:51 PM
News IconHC Stocks to watch for: Kite Pharma Inc (KITE), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) - share market updates (press release) (NASDAQ:KITE)
sharemarketupdates.com - August 30 at 9:05 AM

Social

Kite Pharma (NASDAQ:KITE) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff